The effect of recombinant human erythropoietin (r-Hu EPO) administration on the blood chemistries and composition in uremic rats.
Recombinant human erythropoietin (r-Hu EPO) therapy improves the anaemia of patients on chronic hemodialysis, on peritoneal dialysis and those with chronic renal failure who have not yet started any form of renal replacement therapy. In the last category there is concern that r-Hu EPO therapy may be associated with deterioration of the reserve renal function. But new data showed that even during more prolonged treatment the correction of anaemia does not have a major detrimental effect on renal function. The study was undertaken to examine the influence of r-Hu EPO therapy on renal function and rheological erythrocytes finding in uremic rats.
Kozioł
M
M
Klinika Nefrologii Akademii Medycznej, Lublinie.
Ksiazek
P
P
Feldo
M
M
Spasiewicz
D
D
Michalak
J
J
Kleinrok
Z
Z
D000818:Animals; D003404:Creatinine / Q000097:blood; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000627:therapeutic use*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000627:therapeutic use; D014508:Urea / Q000097:blood; D014511:Uremia / Q000097:blood* / Q000628:therapy*
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D014508:Urea; D003404:Creatinine